RASAGILINE MESYLATE · TORRENT
Rasagiline mesylate is a monoamine oxidase (MAO)-B inhibitor indicated for the treatment of patients with Parkinson’s disease. The medication is used to manage the symptoms of the condition by modulating neurotransmitter levels in the central nervous system. It serves as a therapeutic intervention to address motor dysfunction associated with the loss of dopaminergic activity.
How RASAGILINE MESYLATE Works
Rasagiline acts as a selective and irreversible inhibitor of monoamine oxidase type B (MAO-B), an enzyme responsible for the metabolic degradation of catecholamines in the brain. By blocking this enzyme, the drug increases extracellular levels of dopamine in the striatum. This elevated dopamine level enhances dopaminergic activity, which is believed to mediate the drug's beneficial effects on motor function.
Details
- Status
- Prescription
- First Approved
- 2006-05-16
- Routes
- ORAL
- Dosage Forms
- TABLET
Companies
RASAGILINE MESYLATE Approval History
What RASAGILINE MESYLATE Treats
1 indicationsRASAGILINE MESYLATE is approved for 1 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.
RASAGILINE MESYLATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to RASAGILINE MESYLATE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
1 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT00977665 results posted | MSA-RAS-202 2009-014644-11 | Ph 2 | completed | Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
RASAGILINE MESYLATE FDA Label Details
Indications & Usage
FDA Label (PDF)Rasagiline tablets are indicated for the treatment of Parkinson’s disease (PD). Rasagiline tablets, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson's disease
Looking for the branded version?
AZILECT
Full clinical data, patents, trials, and competitive landscape for rasagiline mesylate.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.